Cargando…
Tanshinone IIA Reverses Oxaliplatin Resistance In Human Colorectal Cancer Via Inhibition Of ERK/Akt Signaling Pathway
BACKGROUND: Oxaliplatin (OXA)-based chemotherapy is generally used to treat human cancers, whereas OXA resistance is a main obstacle for the treatment of colorectal cancer (CRC). Evidence has shown that tanshinone IIA (Tan IIA) could induce apoptosis in CRC cells. However, the role of combination of...
Autores principales: | Zhang, Yonggang, Ge, Tingrui, Xiang, Ping, Zhou, Jingyi, Tang, Shumin, Mao, Haibing, Tang, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859961/ https://www.ncbi.nlm.nih.gov/pubmed/32009805 http://dx.doi.org/10.2147/OTT.S217914 |
Ejemplares similares
-
Tanshinone IIA reverses oxaliplatin resistance in colorectal cancer through microRNA-30b-5p/AVEN axis
por: Ge, Tingrui, et al.
Publicado: (2022) -
Inhibition of miR-96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1
por: Ge, Tingrui, et al.
Publicado: (2020) -
Therapeutic effect of protease-activated receptor 2 agonist SLIGRL-NH(2) on loperamide-induced Sprague-Dawley rat constipation model and the related mechanism
por: Zhang, Yonggang, et al.
Publicado: (2018) -
Effect of Supplementation of Tanshinone IIA and Sodium Tanshinone IIA Sulfonate on the Anticancer Effect of Epirubicin: An In Vitro Study
por: Chan, Szu-Erh, et al.
Publicado: (2011) -
Renoprotective Effects of Tanshinone IIA: A Literature Review
por: Chen, Zhengtao, et al.
Publicado: (2023)